Intermountain, Amgen Subsidiary Launch DNA Mapping Effort

Health Data Management

June 13, 2019

By Greg Slabodkin

Intermountain Healthcare is teaming with a human genome analytics vendor for what it contends is the largest and most comprehensive domestic DNA mapping effort to date from a single population.

The study, which will involve the collection of half a million DNA samples from Intermountain Healthcare’s patient population, seeks to establish new links between genetics and diseases such as breast cancer, colon cancer and heart disease.

Intermountain Healthcare

Iceland-based deCODE genetics—a wholly owned subsidiary of Amgen—has discovered genetic risk factors for dozens of common diseases and will analyze the genomes of the study’s 500,000 participants, who will consent to the testing and have the option to receive their genetic results report if a clinically significant gene mutation is identified.

“While the 500,000 samples will be collected primarily from patients in Utah, the research is expected to have a global impact as medications, treatments, and healthcare innovations that can benefit patients universally are developed from the findings,” says Lincoln Nadauld, MD, Intermountain’s chief of precision health. “The collaboration is noteworthy and unique in its size, scope and immediate application to patient care.”

Posted in: Precision Medicine, R&D

Post a Comment

You must be logged in to post a Comment.